Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

Ceapro Inc. Initiates Next Phase of Scale-Up of Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets, The Canadian Business Journal

  • PGX processing unit installed at University of Alberta’s Agri-Food Discovery Place
  • Alginic acid and yeast beta-glucan will be the first bioactives processed at this location

EDMONTON, Alberta, November 7, 2022 (GLOBE NEWSWIRE) — seapro Co., Ltd.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for the healthcare and cosmetics industries, today announced with the Governor of the University of Alberta that it has been named a designated Agri-Food Discovery Announced that they have signed a license agreement to use the area. Place (AFDP) further scales up its disruptive pressurized gas expansion (PGX) technology in preparation for a commercial partnership.

The signing of this agreement follows last month’s announcement that the company has successfully demonstrated superior bioavailability results using new chemical conjugates, PGX alginate and PGX yeast beta-glucan, as delivery systems for coenzyme Q10. It is done. Ceapro demonstrated significantly improved tissue delivery of a bioactive substance notoriously poor in bioavailability compared to the current gold standard for oral CoQ10 supplementation. This, combined with data showing that PGX can create fast- or slow-release versions of his CoQ10 and other bioactives, and deliver them in unique formats such as functional drinks and fast-dissolving strips, has made PGX support the possibility of Transforming the delivery of drugs and bioactives, ultimately enabling the creation of best-in-class nutraceuticals and pharmaceuticals.

“These unprecedented results support our investment decision to scale PGX technology to the next level with the aim of increasing capacity by a factor of 5-10 compared to our current demo plant facility. The signing of a license agreement to scale up the PGX technology using designated areas within the Agri-Food Discovery Place (AFDP) is an additional and deliberate step in this process that ultimately has great potential. This next phase of scale-up will enable us to work with our commercial partners in nutraceuticals and pharmaceuticals to develop new functional foods and beverages, It will enable us to formulate, test and commercialize new products and formulations, including new drugs and various forms of delivery systems.”, MSc, MBA, President and CEO.

“Ceapro’s team and board are very enthusiastic about all of our findings and developments as they more clearly demonstrate the untapped potential of PGX technology. The decision to sign and invest in a larger customized PGX unit is based on the fact that AFDP’s facilities, part of the Department of Agro-Food and Nutritional Sciences at the University of Alberta, have the appropriate infrastructure. The PGX technology must be safely and conveniently scaled up to produce the human-grade materials designed for oral delivery required to meet regulatory authorities and partners. It is the “home” of Dr. Feral Temelli, who was an active participant in the design and implementation, and developed the PGX technology as part of numerous projects. This scale-up effort will be coordinated with two of her specialist engineering firms currently evaluating designs to further define timelines and costs for this project, which will be financed using current cash on hand. ” MBA, President and CEO.

The scale-up of PGX technology at AFDP mainly involves processing sodium alginate (ALG) extracted from brown seaweed and yeast beta-glucan (YBG) extract from brewer’s yeast to produce PGX-treated alginate (PGX-ALG). Focus on forming. It is a processed yeast beta-glucan (PGX-YBG), both of which have wide applications in both nutraceuticals and pharmaceuticals. “Using any of these PGX composites as a carrier significantly increases not only bioavailability, which refers to the amount of drug, nutrient, or bioactive agent, but also the amount of drug or bioactive agent that can be loaded into a single dosage. Dr. Bernhard Seifried, Senior Director of Research & Technology at Ceapro, explains:

“Instead of a tablet that needs to be swallowed with water, PGX-ALG can also be made into a thin strip that instantly dissolves on the tongue. Although of limited efficacy, in vitro studies have shown that treatment with PGX significantly improves immune-enhancing effects. Research collaborations have shown that PGX-YBG, due to its high purity and uniquely small particle size, can also serve as a means of delivering therapeutics via inhalation, reaching tissues that would otherwise be unreachable. has the potential to transform the treatment of difficult-to-treat conditions like pulmonary fibrosis,” added Dr. Sefried.

About Pressurized Gas Expanded Liquid Technology (PGX)
Ceapro’s patented pressurized gas expansion (PGX) technology is a unique and disruptive technology with several key advantages over traditional drying and purification techniques, making biopolymers into high-value, microstructured can be used to fabricate into open-porous polymer structures and novel biocomposites. PGX technology is ideal for processing challenging high molecular weight, water-soluble biopolymers. It has the ability to continuously create ultra-lightweight, highly porous polymer structures that are not possible with today’s conventional technology. The PGX technology was invented by Dr. Bernhard Seifried, his Senior Director of Research and Technology at Ceapro, and his Dr. Feral Temelli in the Department of Agriculture, Food and Nutritional Sciences at the University of Alberta (U of A). A license from the U of A gives Ceapro exclusive worldwide rights in all industrial applications.

About the University of Alberta
The University of Alberta in Edmonton is one of Canada’s top teaching and research universities, with an international reputation for excellence in the humanities, sciences, creative arts, business, engineering and health sciences. It’s one. With over 38,000 students and over 15,000 faculty members, the university has an annual budget of $1.9 billion and collects over $500 million in funded research income. The U of A offers nearly 900 rigorous undergraduate, postgraduate and professional programs in 18 faculties on 5 campuses, including 1 rural campus and 1 French-speaking campus. The university has over 275,000 alumni worldwide. The university and its people continue to live up to the promise President Henry Marshall Tory made in his 1908 that knowledge will be used to “uplift all nations.”

About Seapro Co., Ltd.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant sources. Ceapro adds further value to its extracts by supporting their use in cosmeceuticals, nutraceuticals and therapeutic products for humans and animals. We have extensive expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills converge in the areas of active ingredients, biopharmaceuticals and drug delivery solutions. For more information on Ceapro, visit his website at: www.ceapro.com.

For more information, please contact:
jene thomas
Investor Relations and Corporate Communications Advisor
Phone (US): +1 (833) 475-8247
E: [email protected]

Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this release.

CBJ Newsmaker

Ceapro Inc. Initiates Next Phase of Scale-Up of Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets, The Canadian Business Journal

Source link Ceapro Inc. Initiates Next Phase of Scale-Up of Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets, The Canadian Business Journal

Related Articles

Back to top button